Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SAT1 | P21673 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SHBG | P04278 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13999522 | 1.00 | SAT1 (0.38) | SAT1JAK2JAK1TYK2TDP1 | |
| SCHEMBL13999524 | 1.00 | SAT1 (0.38) | SAT1JAK2JAK1TYK2TDP1 | |
| SCHEMBL8259142 | 0.88 | — | — | |
| SCHEMBL14176504 | 0.88 | SAT1 (0.39) | SAT1JAK2JAK1TYK2TDP1 | |
| SCHEMBL24775478 | 0.87 | CYP3A4 (0.33) | SAT1 | |
| SCHEMBL13999478 | 0.82 | SAT1 (0.38) | SAT1JAK2JAK1TYK2TDP1 | |
| SCHEMBL23509269 | 0.81 | SAT1 (0.34) | SAT1SHBGDPP4 | |
| SCHEMBL24775165 | 0.79 | SAT1 (0.39) | SAT1JAK2JAK1TYK2 | |
| SCHEMBL24775183 | 0.79 | SAT1 (0.34) | SAT1JAK2JAK1TYK2 | |
| SCHEMBL25743739 | 0.79 | SAT1 (0.34) | SAT1JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
| US-20130065883-A1 | Triazolo [4, 5- B] Pyridin Derivatives | Centro Nacional de Investigaceiones Oncologicas (CNIO) (ES) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | SAT1 4790/4885JAK2 439/4885JAK1 2705/4885 |
| US-20130065883-A1 | Triazolo [4, 5- B] Pyridin Derivatives | PIM1, PIM3, PIM2 | SAT1 995/4885JAK2 13/4885JAK1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.